Research location

Brasília

Brazil

Published trials115

Site observations143

Linked trials published115

Page1 / 3

Research activity in Brasília

Brazil

CureCurrent currently publishes aggregate city-level research activity for this location: 115 trials and 143 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Brasília

115 linked trials · page 1 of 3

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117 · 2026-08-24 · 1 site observation

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes MellitusNCT07784725 · 2026-08-19 · 1 site observation

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusNCT07662213 · 2026-07-06 · 1 site observation

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes MellitusNCT07662109 · 2026-07-06 · 1 site observation

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DMNCT07667803 · 2026-06-29 · 1 site observation

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseNCT07492641 · 2026-05-22 · 1 site observation

A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical StudiesNCT07606066 · 2026-05-06 · 1 site observation

A Study of Brenipatide in Adult Participants With SchizophreniaNCT07410507 · 2026-02-10 · 1 site observation

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesNCT07321886 · 2026-02-06 · 1 site observation

TIL-Driven De-escalated Chemotherapy in Stage I-II TNBCNCT07074106 · 2025-10-31 · 1 site observation

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerNCT07173751 · 2025-10-30 · 1 site observation

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109 · 2025-09-22 · 2 site observations

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseNCT07064473 · 2025-07-22 · 1 site observation

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightNCT06937099 · 2025-06-26 · 1 site observation

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyNCT06937086 · 2025-06-26 · 1 site observation

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartNCT06935370 · 2025-05-20 · 3 site observations

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)NCT06883305 · 2025-03-18 · 1 site observation

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinNCT06677060 · 2025-03-14 · 1 site observation

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureNCT06742723 · 2025-03-03 · 1 site observation

Study That Will Evaluate the Brazilian Population With COPD.NCT06780046 · 2025-01-31 · 1 site observation

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)NCT06672549 · 2024-11-18 · 1 site observation

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerNCT06435429 · 2024-08-13 · 1 site observation

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia SymptomsNCT06559306 · 2024-07-25 · 1 site observation

Agnostic Therapy in Rare Solid TumorsNCT06638931 · 2024-07-16 · 1 site observation

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailureNCT06424288 · 2024-06-17 · 5 site observations

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionNCT06307652 · 2024-04-12 · 1 site observation

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseNCT06283966 · 2024-02-21 · 4 site observations

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast CancerNCT05950945 · 2023-12-30 · 1 site observation

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNCT06119581 · 2023-12-21 · 1 site observation

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsNCT06120283 · 2023-12-01 · 1 site observation

ACP-204 in Adults With Alzheimer's Disease PsychosisNCT06159673 · 2023-11-14 · 2 site observations

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31 · 2 site observations

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · 2022-12-12 · 1 site observation

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or OverweightNCT06962280 · 2025-05-12 · 1 site observation

ACTIVE_NOT_RECRUITING

Nipocalimab in Moderate to Severe Sjogren's DiseaseNCT06741969 · 2024-12-04 · 1 site observation

ACTIVE_NOT_RECRUITING

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological FeaturesNCT06564844 · 2024-10-15 · 1 site observation

ACTIVE_NOT_RECRUITING

The OPBC-07/microNAC StudyNCT06529302 · 2024-05-15 · 2 site observations

ACTIVE_NOT_RECRUITING

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · 2024-04-30 · 2 site observations

ACTIVE_NOT_RECRUITING

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension StudyNCT06194799 · 2024-04-23 · 1 site observation

ENROLLING_BY_INVITATION

Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)NCT06122961 · 2023-11-23 · 1 site observation

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 · 2023-11-20 · 2 site observations

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerNCT06112379 · 2023-11-14 · 1 site observation

ACTIVE_NOT_RECRUITING

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)NCT05952557 · 2023-10-05 · 1 site observation

ACTIVE_NOT_RECRUITING

ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer StudyNCT05596409 · 2023-05-19 · 1 site observation

ACTIVE_NOT_RECRUITING

Nodal Burden and Nodal Recurrence in Patients With Isolated Tumor Cells After Neoadjuvant Chemotherapy Treated With Axillary Dissection or Nodal Radiation: the OPBC-05/EUBREAST-14R/ICARO StudyNCT06464341 · 2023-05-04 · 1 site observation

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskNCT05803421 · 2023-04-03 · 2 site observations

Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).NCT05742802 · 2023-03-06 · 1 site observation

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerNCT05608044 · 2022-11-30 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)NCT05629585 · 2022-11-28 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityNCT05556512 · 2022-10-11 · 2 site observations

ACTIVE_NOT_RECRUITING

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.